Latest Report Titled On:- Asia-Pacific Diabetes Care Drugs Market – Growth, Trends, and Forecast (2019 – 2024)
360 MARKET UPDATES Report provides a 360-degree overview of the global Asia-Pacific Diabetes Care Drugs market with special emphasis on all aspects including drivers, restraints, and opportunities, market and regional segmentation.
Global Asia-Pacific Diabetes Care Drugs Market report (2019 – 2024) focuses on market overview, scope of report, share, current market trends and upcoming future predictions.
Get Sample PDF Of Report – https://www.360marketupdates.com/enquiry/request-sample/13782530
Asia-Pacific Diabetes Care Drugs Market Report Covers Leading Manufacturers: Takeda , Pfizer , Eli Lilly , Janssen Pharmaceuticals , Astellas , Boehringer Ingelheim , Merck And Co. , AstraZeneca , Bristol Myers Squibb , Novartis , Sanofi
The Asia-Pacific Diabetes Care Drugs Market Overview:
The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.
Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population.
The Asian population gets diabetes at a younger age in comparison to the Western population. The reason for this early diabetes development is the sudden change in lifestyle, due to rapid economic growth.
Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia.
Inquire for further detailed information about Asia-Pacific Diabetes Care Drugs Market Report – http://www.360marketupdates.com/enquiry/pre-order-enquiry/13782530
123 – Oral Anti-Diabetes Drugs Take 67% of the Asia-Pacific Diabetes Drugs Market.
The use of oral anti-diabetes drugs is rising, due to the fact that new generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.
SGLT-2 and GLP-1 are linked to lowering the mortality rate more effectively than DPP-4 inhibitors.
Meglitinide and sulfonylureas are oral hypoglycemic drugs that directly arouse the discharge of insulin from pancreatic beta cells. They hold a significant market share, of 14.27% and 9.62%, respectively, in the Asia-Pacific anti-diabetics drugs market.
China and Japan Occupy more than a 50% Share in the Asia-Pacific Diabetes Drugs Market.
In the Asia-Pacific region, China and Japan have recognized as potential developing markets, due to the growing diabetic population in this region.
Japan is a mature market, with some associated challenges, like slow economic growth, the aging population, and increased competition. One particular challenge in this region is the growing preference for oral anti-diabetics among type-2 diabetic patients, thereby, leading to a negative insulin volume development.
China has the highest market share and is expected to grow with a steady CAGR of 4%. It also contributes 15% to the global diabetes drugs market.
The country is witnessing a significant increase in the number of generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.
The Scope of Asia-Pacific Diabetes Care Drugs Market:
The Asia-Pacific diabetes drugs report covered by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by countries.
Order Full Copy of Report – https://www.360marketupdates.com/purchase/13782530
Reasons to Purchase this Report:
- Current and future of Global Smart Cities Market outlook in the developed and emerging markets
• Analysing various perspectives of the market with the help of Porter’s five forces analysis
• Report customization as per the client’s requirements
• Regions that are expected to witness fastest growth during the forecast period
• Identifying the latest developments, market shares and strategies employed by the major market players
• 3 month analyst support, along with the Market Estimate sheet (in Excel)
About 360 Market Updates:
360 Market Updates is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Market Updates, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.
Name: Mr. Ajay More
Organization: 360 Market Updates
Phone: +14242530807/+44 203 239 8187
Tagged: Google News, Asia-Pacific Diabetes Care Drugs Market, Asia-Pacific Diabetes Care Drugs Europe Market, Asia-Pacific Diabetes Care Drugs APAC Market, Asia-Pacific Diabetes Care Drugs Market By Application, Asia-Pacific Diabetes Care Drugs Market By Rising Trends, Asia-Pacific Diabetes Care Drugs Market Development, Asia-Pacific Diabetes Care Drugs Market Forecast, Asia-Pacific Diabetes Care Drugs Market Future, Asia-Pacific Diabetes Care Drugs Market Growth, Asia-Pacific Diabetes Care Drugs Market In Key Countries, Asia-Pacific Diabetes Care Drugs Market Latest Report, Asia-Pacific Diabetes Care Drugs Market Swot Analysis, Asia-Pacific Diabetes Care Drugs Market Top Manufacturers, Asia-Pacific Diabetes Care Drugs Sales Market, Asia-Pacific Diabetes Care Drugs United States Market